Effectiveness of COVID-19 MRNA Vaccines Against COVID-19–associated Hospitalization — Five Veterans Affairs Medical Centers, United States, February 1–August 6, 2021

Details

• Personal Author:
  Bajema, Kristina L. ; Dahl, Rebecca M. ; Prill, Mila M. ; Meites, Elissa ; Rodriguez-Barradas, Maria C. ; Marconi, Vincent C. ; Beenhouwer, David O. ; Brown, Sheldon T. ; Holodniy, Mark ; Lucero-Obusan, Cynthia ; Rivera-Dominguez, Gilberto ; Morones, Rosalba Gomez ; Whitmire, Alexis ; Goldin, Evan B. ; Evener, Steve L. ; Tremarelli, Maraia ; Tong, Suxiang ; Hall, Aron J. ; Schrag, Stephanie J. ; McMorrow, Meredith ; Kobayashi, Miwako ; Verani, Jennifer R. ; Surie, Diya
• Corporate Authors:
  CDC COVID-19 Response Team. ; Michael E. DeBakey Veterans Affairs Medical Center (Houston, Tex.) ; Baylor College of Medicine. Department of Medicine. ; Veterans Affairs Medical Center (Atlanta, Ga.) ; Emory University School of Medicine. Department of Medicine. ; Rollins School of Public Health. Department of Global Health. ; Greater Los Angeles Veterans Affairs Healthcare System (U.S.). ; David Geffen School of Medicine. Department of Medicine. ; James J. Peters Veterans Affairs Medical Center (Bronx, NY) ; Icahn School of Medicine at Mount Sinai. Department of Medicine. ; VA Palo Alto Health Care System (U.S.) ; United States Department of Veterans Affairs. 12Public Health Surveillance and Research. ; Stanford University School of Medicine.Department of Medicine. ; Karna, LLC. ; General Dynamics Information Technology.
• Description:
  What is already known about this topic? mRNA COVID-19 vaccines are effective in preventing severe COVID-19 outcomes, including hospitalization.
  
  What is added by this report? During February 1–August 6, 2021, vaccine effectiveness among U.S. veterans hospitalized at five Veterans Affairs Medical Centers was 87%. mRNA COVID-19 vaccines remain highly effective, including during periods of widespread circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variants. Vaccine effectiveness in preventing COVID-19–related hospitalization was 80% among adults aged ≥65 years compared with 95% among adults aged 18–64 years.
  
  What are the implications for public health practice? To protect against COVID-19–related hospitalization, all eligible persons should receive COVID-19 vaccination. Additional studies are needed to understand differences in COVID-19 vaccine effectiveness across age groups.
  
  Suggested citation for this article: Bajema KL, Dahl RM, Prill MM, et al. Effectiveness of COVID-19 mRNA Vaccines Against COVID-19–Associated Hospitalization — Five Veterans Affairs Medical Centers, United States, February 1–August 6, 2021. MMWR Morb Mortal Wkly Rep. ePub: 10 September 2021.
  
  mm7037e3.htm?s_cid=mm7037e3_w
  
  mm7037e3-H.pdf
  
  
• Subjects:
  Adult CoronaVirus Infections COVID-19 Vaccines COVID-19/Prevention & Control Hospitalization Hospitals, Veterans Vaccination Vaccines, Synthetic
• Source:
  MMWR: Morbidity and Mortality Weekly Report 2021; v. 70 Early Release
• Series:
  Weekly Report: Morbidity and Mortality Weekly Report (MMWR)
• ISSN:
  0149-2195 (print) ; 1545-861X (digital)
• Document Type:
  Journal Article
• Name as Subject:
  Moderna Covid-19 Vaccine ; Pfizer-BioNTech COVID-19 Vaccine
• Place as Subject:
  United States
• Pages in Document:
  7 pdf pages
• Volume:
  70
• Collection(s):
  Morbidity and Mortality Weekly Report (MMWR)
• Main Document Checksum:
  urn:sha-512:f5761d5f33ee003285a416fd03912551a721955e6ab682a112079300f49c8027fdaca512bebcca8f152531e1fb3ea46b1acc29bfa7417bb40ed601bbd3ca47ae
• Download URL:
  https://stacks.cdc.gov/view/cdc/109689/cdc_109689_DS1.pdf
• File Type:
  [PDF - 261.32 KB ]